DLA Piper advises EQT Ventures on a seed round in start-up Origin.Bio

DLA Piper has advised EQT Ventures on its investment in Munich-based start-up Origin.Bio in a USD15 million seed round. In addition to EQT Ventures, other backers include Blueyard Capital and Inventures.

Launched in 2021, Origin.Bio is a synthetic biology company which connects bioengineers with nature. It creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialisation processes today, but with significantly less energy requirements and waste produced, while eradicating the need for petrochemicals. The company is bridging the gap between leading R&D-focused organisations and brands/OEMS to scale climate focused innovation.

EQT Ventures is the venture capital fund of Swedish private equity fund EQT Partners. EQT Ventures invests globally in fast-growing, innovative and technology-driven companies across all sectors, with a focus on Europe and the US.

The DLA Piper team led by partner Andreas Füchsel (Private Equity/M&A) also comprised of partner Semin O (Litigation & Regulatory), counsel Kaja Herrmann (Employment), senior associate Philipp Groll (Private Equity/M&A) as well as associates Alexander Rösch (Litigation & Regulatory), Johannes Klug (Employment, all Frankfurt) and Jessica Herrmann (Corporate, Munich).